UroGen Pharma Ltd. - Ordinary Shares (URGN) Social Stream
UROGEN PHARMA LTD (URGN) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering UROGEN PHARMA LTD.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-08-05 | 5 | $55 | $30 | $46.5 | $9.33 | 398.39% |
| 2021-11-11 | 4 | $55 | $30 | $46.5 | $9.33 | 398.39% |
| 2021-11-16 | 5 | $51 | $30 | $44 | $9.33 | 371.6% |
| 2022-03-02 | 5 | $51 | $30 | $40 | $9.33 | 328.72% |
| 2022-03-23 | 4 | $51 | $17 | $31 | $9.33 | 232.26% |
| 2022-04-27 | 6 | $51 | $17 | $27 | $9.33 | 189.39% |
| 2022-07-21 | 5 | $51 | $17 | $27 | $9.33 | 189.39% |
| 2022-08-12 | 6 | $51 | $17 | $27 | $9.33 | 189.39% |
| 2022-08-15 | 6 | $51 | $17 | $29.8 | $9.33 | 219.4% |
| 2022-10-26 | 6 | $51 | $20 | $34.4 | $9.33 | 268.7% |
| 2022-11-10 | 6 | $51 | $20 | $33.4 | $9.33 | 257.98% |
| 2022-11-14 | 6 | $47 | $20 | $32.6 | $9.33 | 249.41% |
| 2022-11-23 | 6 | $47 | $20 | $30.8 | $9.33 | 230.12% |
| 2022-12-20 | 6 | $47 | $20 | $30.2 | $9.33 | 223.69% |
| 2023-02-16 | 6 | $47 | $10 | $25.2 | $9.33 | 170.1% |
The Trend in the Analyst Price Target
URGN's average price target has moved down $13.97 over the prior 20 months.
Over the past 47 weeks, URGN's average upside potential has been 249.56%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-03-23 | 4 | 51 | 17 | 31.0 | 8.31 | 273.04% |
| 2022-10-26 | 6 | 51 | 20 | 34.4 | 11.66 | 195.03% |
| 2022-11-10 | 6 | 51 | 20 | 33.4 | 9.18 | 263.83% |
| 2022-11-14 | 6 | 47 | 20 | 32.6 | 9.16 | 255.9% |
| 2023-02-16 | 6 | 47 | 10 | 25.2 | 9.41 | 167.8% |
URGN Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.33 | 5 | 0 | 1 | 0 | 0 | 6 |
The Trend in the Broker Recommendations
URGN's average broker recommendation rating worsened by 0.33 over the prior 13 months.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- URGN has a greater upside potential (average analyst target price relative to current price) than 1477.44% of all US stocks.
- In terms of how UROGEN PHARMA LTD fares relative to all US stocks, note that its variance in analysts' estimates is lower than -1232.32% of that group.
- UROGEN PHARMA LTD's number of analysts covering the stock is higher than 430.67% of all US stocks.
- In the context of stocks in the small market cap category, UROGEN PHARMA LTD's average analyst price target is greater than 1314.03% of them.
In the Pharmaceutical Products industry, PRTK, VBIV, and ATNF are the three stocks most similar to UROGEN PHARMA LTD regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Is URGN a Buy, Hold or Sell? See the POWR Ratings now!